APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD79a Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CD79a Antibody Market Outlook and Growth Opportunities 2026

19 December 2025199 pages

Choose your research edition.

Industry ResearchCD79a Antibody Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal CD79a Antibody Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal CD79a Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD79a Antibody Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal CD79a Antibody Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global CD79a Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CD79a Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CD79a Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CD79a Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CD79a Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CD79a Antibody market include Aviva Systems Biology, Beckman Coulter, BioLegend, Bio-Rad, EXBIO, FineTest, Hytest, Miltenyi Biotec and NSJ Bioreagents, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CD79a Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CD79a Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CD79a Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CD79a Antibody market.

CD79a Antibody Segment by Company

Aviva Systems Biology

Beckman Coulter

BioLegend

Bio-Rad

EXBIO

FineTest

Hytest

Miltenyi Biotec

NSJ Bioreagents

Proteintech

Santa Cruz Biotechnology

Thermo Fisher Scientific

CD79a Antibody Segment by Type

Polyclonal

Monoclonal

CD79a Antibody Segment by Application

Immunohistochemistry

Immunofluorescence

Enzyme Linked Immunosorbent Assay

Western Blot

Others

CD79a Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global CD79a Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CD79a Antibody key companies, revenue, market share, and recent developments.

3. To split the CD79a Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CD79a Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CD79a Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze CD79a Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD79a Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD79a Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD79a Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CD79a Antibody industry.

Chapter 3: Detailed analysis of CD79a Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CD79a Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CD79a Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CD79a Antibody Industry Trends Table 2. CD79a Antibody Industry Drivers Table 3. CD79a Antibody Industry Opportunities and Challenges Table 4. CD79a Antibody Industry Restraints Table 5. Global CD79a Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CD79a Antibody Revenue Share by Company (2021-2026) Table 7. Global CD79a Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CD79a Antibody Key Company Manufacturing Base & Headquarters Table 9. Global CD79a Antibody Company, Product Type & Application Table 10. Global CD79a Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CD79a Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global CD79a Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global CD79a Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global CD79a Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global CD79a Antibody Sales Value Share by Type (2021-2026) Table 20. Global CD79a Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Table 22. Significant Companies of Immunofluorescence Table 23. Significant Companies of Enzyme Linked Immunosorbent Assay Table 24. Significant Companies of Western Blot Table 25. Significant Companies of Others Table 26. Global CD79a Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global CD79a Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global CD79a Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global CD79a Antibody Sales Value Share by Application (2021-2026) Table 30. Global CD79a Antibody Sales Value Share by Application (2027-2032) Table 31. Global CD79a Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global CD79a Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global CD79a Antibody Sales Value Share by Region (2021-2026) Table 34. Global CD79a Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global CD79a Antibody Sales Value Share by Region (2027-2032) Table 36. Global CD79a Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global CD79a Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global CD79a Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global CD79a Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global CD79a Antibody Sales Value Market Share by Country (2027-2032) Table 41. Aviva Systems Biology Company Information Table 42. Aviva Systems Biology Business Overview Table 43. Aviva Systems Biology CD79a Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Aviva Systems Biology CD79a Antibody Product Portfolio Table 45. Aviva Systems Biology Recent Development Table 46. Beckman Coulter Company Information Table 47. Beckman Coulter Business Overview Table 48. Beckman Coulter CD79a Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Beckman Coulter CD79a Antibody Product Portfolio Table 50. Beckman Coulter Recent Development Table 51. BioLegend Company Information Table 52. BioLegend Business Overview Table 53. BioLegend CD79a Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. BioLegend CD79a Antibody Product Portfolio Table 55. BioLegend Recent Development Table 56. Bio-Rad Company Information Table 57. Bio-Rad Business Overview Table 58. Bio-Rad CD79a Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Bio-Rad CD79a Antibody Product Portfolio Table 60. Bio-Rad Recent Development Table 61. EXBIO Company Information Table 62. EXBIO Business Overview Table 63. EXBIO CD79a Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. EXBIO CD79a Antibody Product Portfolio Table 65. EXBIO Recent Development Table 66. FineTest Company Information Table 67. FineTest Business Overview Table 68. FineTest CD79a Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. FineTest CD79a Antibody Product Portfolio Table 70. FineTest Recent Development Table 71. Hytest Company Information Table 72. Hytest Business Overview Table 73. Hytest CD79a Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Hytest CD79a Antibody Product Portfolio Table 75. Hytest Recent Development Table 76. Miltenyi Biotec Company Information Table 77. Miltenyi Biotec Business Overview Table 78. Miltenyi Biotec CD79a Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Miltenyi Biotec CD79a Antibody Product Portfolio Table 80. Miltenyi Biotec Recent Development Table 81. NSJ Bioreagents Company Information Table 82. NSJ Bioreagents Business Overview Table 83. NSJ Bioreagents CD79a Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. NSJ Bioreagents CD79a Antibody Product Portfolio Table 85. NSJ Bioreagents Recent Development Table 86. Proteintech Company Information Table 87. Proteintech Business Overview Table 88. Proteintech CD79a Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Proteintech CD79a Antibody Product Portfolio Table 90. Proteintech Recent Development Table 91. Santa Cruz Biotechnology Company Information Table 92. Santa Cruz Biotechnology Business Overview Table 93. Santa Cruz Biotechnology CD79a Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Santa Cruz Biotechnology CD79a Antibody Product Portfolio Table 95. Santa Cruz Biotechnology Recent Development Table 96. Thermo Fisher Scientific Company Information Table 97. Thermo Fisher Scientific Business Overview Table 98. Thermo Fisher Scientific CD79a Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Thermo Fisher Scientific CD79a Antibody Product Portfolio Table 100. Thermo Fisher Scientific Recent Development Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. CD79a Antibody Product Image Figure 2. Global CD79a Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD79a Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global CD79a Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global CD79a Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global CD79a Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global CD79a Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Image Figure 13. Immunofluorescence Image Figure 14. Enzyme Linked Immunosorbent Assay Image Figure 15. Western Blot Image Figure 16. Others Image Figure 17. Global CD79a Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global CD79a Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global CD79a Antibody Sales Value Share by Application (2021-2032) Figure 20. Global CD79a Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global CD79a Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America CD79a Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America CD79a Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe CD79a Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe CD79a Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific CD79a Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific CD79a Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America CD79a Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America CD79a Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa CD79a Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa CD79a Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt CD79a Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt CD79a Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt CD79a Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry
  • Immunofluorescence
  • Enzyme Linked Immunosorbent Assay
  • Western Blot
  • Others
Companies covered
  • Aviva Systems Biology
  • Beckman Coulter
  • BioLegend
  • Bio-Rad
  • EXBIO
  • FineTest
  • Hytest
  • Miltenyi Biotec
  • NSJ Bioreagents
  • Proteintech
  • Santa Cruz Biotechnology
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CD79a Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CD79a Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CD79a Antibody Market Dynamics
  1. 2.1 CD79a Antibody Industry Trends
  2. 2.2 CD79a Antibody Industry Drivers
  3. 2.3 CD79a Antibody Industry Opportunities and Challenges
  4. 2.4 CD79a Antibody Industry Restraints
3 CD79a Antibody Market by Company
  1. 3.1 Global CD79a Antibody Company Revenue Ranking in 2025
  2. 3.2 Global CD79a Antibody Revenue by Company (2021-2026)
  3. 3.3 Global CD79a Antibody Company Ranking (2024-2026)
  4. 3.4 Global CD79a Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global CD79a Antibody Company Product Type and Application
  6. 3.6 Global CD79a Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CD79a Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CD79a Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CD79a Antibody Market by Type
  1. 4.1 CD79a Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global CD79a Antibody Sales Value by Type
  5. 4.2.1 Global CD79a Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global CD79a Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global CD79a Antibody Sales Value Share by Type (2021-2032)
5 CD79a Antibody Market by Application
  1. 5.1 CD79a Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry
  3. 5.1.2 Immunofluorescence
  4. 5.1.3 Enzyme Linked Immunosorbent Assay
  5. 5.1.4 Western Blot
  6. 5.1.5 Others
  7. 5.2 Global CD79a Antibody Sales Value by Application
  8. 5.2.1 Global CD79a Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global CD79a Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global CD79a Antibody Sales Value Share by Application (2021-2032)
6 CD79a Antibody Regional Value Analysis
  1. 6.1 Global CD79a Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CD79a Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global CD79a Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global CD79a Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CD79a Antibody Sales Value (2021-2032)
  7. 6.3.2 North America CD79a Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CD79a Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe CD79a Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CD79a Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CD79a Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CD79a Antibody Sales Value (2021-2032)
  16. 6.6.2 South America CD79a Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CD79a Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CD79a Antibody Sales Value Share by Country, 2025 VS 2032
7 CD79a Antibody Country-level Value Analysis
  1. 7.1 Global CD79a Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CD79a Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global CD79a Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global CD79a Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CD79a Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CD79a Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CD79a Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CD79a Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CD79a Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CD79a Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CD79a Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CD79a Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CD79a Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CD79a Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CD79a Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CD79a Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CD79a Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CD79a Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CD79a Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CD79a Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CD79a Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CD79a Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CD79a Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CD79a Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CD79a Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CD79a Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CD79a Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CD79a Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CD79a Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CD79a Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CD79a Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CD79a Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CD79a Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CD79a Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CD79a Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aviva Systems Biology
  2. 8.1.1 Aviva Systems Biology Company Information
  3. 8.1.2 Aviva Systems Biology Business Overview
  4. 8.1.3 Aviva Systems Biology CD79a Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aviva Systems Biology CD79a Antibody Product Portfolio
  6. 8.1.5 Aviva Systems Biology Recent Developments
  7. 8.2 Beckman Coulter
  8. 8.2.1 Beckman Coulter Company Information
  9. 8.2.2 Beckman Coulter Business Overview
  10. 8.2.3 Beckman Coulter CD79a Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Beckman Coulter CD79a Antibody Product Portfolio
  12. 8.2.5 Beckman Coulter Recent Developments
  13. 8.3 BioLegend
  14. 8.3.1 BioLegend Company Information
  15. 8.3.2 BioLegend Business Overview
  16. 8.3.3 BioLegend CD79a Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BioLegend CD79a Antibody Product Portfolio
  18. 8.3.5 BioLegend Recent Developments
  19. 8.4 Bio-Rad
  20. 8.4.1 Bio-Rad Company Information
  21. 8.4.2 Bio-Rad Business Overview
  22. 8.4.3 Bio-Rad CD79a Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bio-Rad CD79a Antibody Product Portfolio
  24. 8.4.5 Bio-Rad Recent Developments
  25. 8.5 EXBIO
  26. 8.5.1 EXBIO Company Information
  27. 8.5.2 EXBIO Business Overview
  28. 8.5.3 EXBIO CD79a Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 EXBIO CD79a Antibody Product Portfolio
  30. 8.5.5 EXBIO Recent Developments
  31. 8.6 FineTest
  32. 8.6.1 FineTest Company Information
  33. 8.6.2 FineTest Business Overview
  34. 8.6.3 FineTest CD79a Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 FineTest CD79a Antibody Product Portfolio
  36. 8.6.5 FineTest Recent Developments
  37. 8.7 Hytest
  38. 8.7.1 Hytest Company Information
  39. 8.7.2 Hytest Business Overview
  40. 8.7.3 Hytest CD79a Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hytest CD79a Antibody Product Portfolio
  42. 8.7.5 Hytest Recent Developments
  43. 8.8 Miltenyi Biotec
  44. 8.8.1 Miltenyi Biotec Company Information
  45. 8.8.2 Miltenyi Biotec Business Overview
  46. 8.8.3 Miltenyi Biotec CD79a Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Miltenyi Biotec CD79a Antibody Product Portfolio
  48. 8.8.5 Miltenyi Biotec Recent Developments
  49. 8.9 NSJ Bioreagents
  50. 8.9.1 NSJ Bioreagents Company Information
  51. 8.9.2 NSJ Bioreagents Business Overview
  52. 8.9.3 NSJ Bioreagents CD79a Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NSJ Bioreagents CD79a Antibody Product Portfolio
  54. 8.9.5 NSJ Bioreagents Recent Developments
  55. 8.10 Proteintech
  56. 8.10.1 Proteintech Company Information
  57. 8.10.2 Proteintech Business Overview
  58. 8.10.3 Proteintech CD79a Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Proteintech CD79a Antibody Product Portfolio
  60. 8.10.5 Proteintech Recent Developments
  61. 8.11 Santa Cruz Biotechnology
  62. 8.11.1 Santa Cruz Biotechnology Company Information
  63. 8.11.2 Santa Cruz Biotechnology Business Overview
  64. 8.11.3 Santa Cruz Biotechnology CD79a Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Santa Cruz Biotechnology CD79a Antibody Product Portfolio
  66. 8.11.5 Santa Cruz Biotechnology Recent Developments
  67. 8.12 Thermo Fisher Scientific
  68. 8.12.1 Thermo Fisher Scientific Company Information
  69. 8.12.2 Thermo Fisher Scientific Business Overview
  70. 8.12.3 Thermo Fisher Scientific CD79a Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Thermo Fisher Scientific CD79a Antibody Product Portfolio
  72. 8.12.5 Thermo Fisher Scientific Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst